PMEF
URGN icon

Point72 Middle East FZE’s UroGen Pharma URGN Stock Holding History

Point72 Middle East FZE’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,941
Closed -$83.2K – 1905
2023
Q3 		$83.2K Buy
+5,941
New +$95.4K ﹤0.01% 1178

Other funds holding URGN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Point72 Middle East FZE's URGN Position: Q4 2023 in Review

Point72 Middle East FZE sold out of UroGen Pharma (URGN) in Q4 2023, closing a stake of 5,941 shares — an estimated $83.2K sold.

Point72 Middle East FZE first reported a position in URGN in Q3 2023 and held it in 1 quarter. The position peaked at $83.2K in Q3 2023. 105 funds tracked by Wall St. Rank hold URGN as of Q4 2023.

  • Point72 Middle East FZE reported no remaining UroGen Pharma position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 5,941 UroGen Pharma shares in Q4 2023, an estimated $83.2K.
  • Point72 Middle East FZE first reported a position in UroGen Pharma in Q3 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's UroGen Pharma position peaked at $83.2K in Q3 2023.
  • 105 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.